Program
zolacabtagene autoleucel
Also written as “CC-97540” and “BMS-986353”.
Its studies are mostly in Scleroderma, Systemic · Multiple Sclerosis · Lupus Erythematosus, Systemic · Lupus Nephritis · Anemia, Hemolytic, Autoimmune, led by Bristol-Myers Squibb.
Furthest: phase 3, since Jan 9, 20266 company-led studies, 5 open or runningNext primary completion: Jul 15, 2027 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Bristol-Myers Squibb | 65 open or running | phase 3since Jan 9, 2026 | Jan 14, 2020 | Jul 15, 2027phase 1 · NCT06220201 |
- Named in Bristol-Myers Squibb’s own pipeline as
zola-cel
, phase 3, as of Oct 29, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jan 14, 2020First study: phase 1 study in Lymphoma, Non-HodgkinFirst studyNCT04231747 · 24 enrolled · United States, Canada
- May 11, 2023Phase 1 study in Lupus Erythematosus, SystemicNCT05869955 · 270 enrolled · United States, Belgium, France and more
- Jan 4, 2024Phase 1 study in Multiple SclerosisNCT06220201 · 120 enrolled · United States, Belgium, France and more
- May 30, 2025Phase 2 study in Lupus Erythematosus, SystemicNCT07015983 · 89 enrolled · United States, Argentina, Austria and more
- Jan 9, 2026Phase 3 study in Scleroderma, SystemicPhase 3 reachedNCT07335562 · 92 planned · United States, Belgium, Canada and more
- May 18, 2026Phase 2 study in Anemia, Hemolytic, AutoimmuneNCT07603557 · 52 planned · United States, Denmark, Germany and more
Ahead
- Jul 15, 2027Primary completion: phase 1 study in Multiple SclerosisNCT06220201
- May 17, 2028Primary completion: phase 2 study in Lupus Erythematosus, SystemicNCT07015983
- Aug 29, 2028Primary completion: phase 1 study in Lupus Erythematosus, SystemicNCT05869955
- Nov 14, 2028Primary completion: phase 3 study in Scleroderma, SystemicNCT07335562
TargetBeta
“A preparation of autologous T-lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) specific for the tumor-associated antigen (TAA) CD19, with potential immunostimulating and antineoplastic activities. Upon administration, zolacabtagene autoleucel specifical…”NCIt, read by Claude
“A preparation of autologous T-lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) specific for the tumor-associated antigen (TAA) CD19, ”NCIt, by rule
Other programs on CD19
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| blinatumomabrule | Amgen | phase 4 | 29 |
| inebilizumabrule | Amgen | phase 4 | 19 |
| Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012F | AstraZeneca | phase 3 | 12 |
| axicabtagene ciloleucelrule | Gilead Sciences | phase 3 | 10 |
| surovatamig | AstraZeneca | phase 3 | 10 |
| lisocabtagene maraleucelrule | Bristol-Myers Squibb | phase 3 | 10 |
| Anti-CD19/CD3 Bispecific Antibody MK-1045 | Merck | phase 3 | 8 |
| obexelimab | zenas-biopharma-usa-llc | phase 3 | 7 |
| Autologous Anti-CD19 CAR-T Cells CABA-201rule | cabaletta-bio | phase 3 | 6 |
| Autologous Anti-CD19/Anti-CD20 CAR-T Cells KITE-753rule | Gilead Sciences | phase 3 | 2 |
| rondecabtagene autoleucelrule | lyell-immunopharma-inc | phase 3 | 2 |
| rapcabtagene autoleucel | Novartis | phase 2 | 8 |
Studies
All 6 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07603557Anemia, Hemolytic, Autoimmune · United States, Denmark, Germany and more | 2 | Not yet recruiting | May 6, 2030 | 52 |
| NCT07335562Scleroderma, Systemic · United States, Belgium, Canada and more | 3 | Not yet recruiting | Nov 14, 2028 | 92 |
| NCT07015983Lupus Erythematosus, Systemic · United States, Argentina, Austria and more | 2 | Active, not recruiting | May 17, 2028 | 89 |
| NCT06220201Multiple Sclerosis · United States, Belgium, France and more | 1 | Active, not recruiting | Jul 15, 2027 | 120 |
| NCT05869955Lupus Erythematosus, Systemic · United States, Belgium, France and more | 1 | Active, not recruiting | Aug 29, 2028 | 270 |
| NCT04231747Lymphoma, Non-Hodgkin · United States, Canada | 1 | Completed | Feb 1, 2024 | 24 |
How it is read
Names in the registry
- “CC-97540”, 4 entries
- “BMS-986353”, 2 entries
Conditions, from the studies’ own filings
- Scleroderma, Systemic, 1 study
- Multiple Sclerosis, 1 study
- Lupus Erythematosus, Systemic, 1 study
- Lupus Nephritis, 1 study
- Anemia, Hemolytic, Autoimmune, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.